Novartis’ Acquisition of Arctos Medical

Walder Wyss advised +ND Capital and the other sellers in the transaction.

Novartis has acquired Arctos Medical, adding a pre-clinical optogenetics-based AAV gene therapy program and Arctos’ proprietary technology to its ophthalmology portfolio.

Arctos developed its technology as a potential method for treating inherited retinal dystrophies (IRDs) and other diseases that involve photoreceptor loss, such as age-related macular degeneration (AMD).

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, they use innovative science and digital technologies to create transformative treatments in areas of great medical need.

The Walder Wyss team was led by Luc Defferrard (Picture – Partner, Corporate/M&A) and further included Dimitrios Berger (Senior Associate, Corporate/M&A), Janine Corti (Counsel, Tax) and Peter Bürkli (Senior Associate, Healthcare & Life Sciences).

Involved fees earner: Peter Bürkli – Walder Wyss Ltd.; Janine Corti – Walder Wyss Ltd.; Luc Defferrard – Walder Wyss Ltd.; Dimitrios Berger – Walder Wyss Ltd.;

Law Firms: Walder Wyss Ltd.;

Clients: +ND Capital;

Author: Federica Tiefenthaler